Online inquiry

IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8948MR)

This product GTTS-WQ8948MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL1RL2 gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_001351446.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8808
UniProt ID Q9HB29
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8948MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14390MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ12030MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ12880MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ14711MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ15214MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ2196MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ14611MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ9871MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA K7153A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW